Immunocore Holdings plc (IMCR) Financial Statements (2025 and earlier)

Company Profile

Business Address 90 PARK DRIVE
OXFORDSHIRE, OX14 4RY
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments859,597832,821 
Cash and cash equivalents504,985832,821 
Short-term investments354,612  
Receivables60,24557,754 
Inventory, net of allowances, customer advances and progress billings3,4624,167 
Inventory3,4624,167 
Other undisclosed current assets33,55531,296 
Total current assets:956,859926,038 
Noncurrent Assets
Operating lease, right-of-use asset32,43532,812 
Property, plant and equipment7,6848,380 
Deferred income tax assets10,11110,761 
Other noncurrent assets16,27615,996 
Total noncurrent assets:66,50667,949 
TOTAL ASSETS:1,023,365993,987 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities36,46628,488 
Accounts payable19,94715,501 
Accrued liabilities16,51912,987 
Debt   
Other undisclosed current liabilities148,630126,805 
Total current liabilities:185,096155,293 
Noncurrent Liabilities
Long-term debt and lease obligation438,121437,544 
Long-term debt, excluding current maturities438,121437,544 
Liabilities, other than long-term debt41,01141,616 
Accounts payable and accrued liabilities2,0892,162 
Deferred revenue5,4775,468 
Operating lease, liability33,44533,986 
Total noncurrent liabilities:479,132479,160 
Total liabilities:664,228634,453 
Equity
Equity, attributable to parent, including:359,137359,534 
Common stock135135 
Additional paid in capital1,174,1471,163,872 
Accumulated other comprehensive loss(34,420)(35,364) 
Accumulated deficit(780,726)(769,110) 
Other undisclosed equity, attributable to parent11 
Total equity:359,137359,534 
TOTAL LIABILITIES AND EQUITY:1,023,365993,987 

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Revenues75,40070,502 
Cost of revenue(1,707)(246) 
Gross profit:73,69370,256 
Operating expenses(89,710)(96,746) 
Operating loss:(16,017)(26,490) 
Nonoperating income10,1645,650 
Investment income, nonoperating6,2398,246 
Gain (loss), foreign currency transaction, before tax(508)(2,406) 
Other nonoperating income (expense)4,433(190) 
Interest and debt expense(4,277)(3,239) 
Income (loss) from continuing operations before income taxes:(10,130)(24,079) 
Income tax expense (benefit)(1,486)(357) 
Net income (loss) available to common stockholders, diluted:(11,616)(24,436) 

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net income (loss):(11,616)(24,436) 
Other comprehensive income944897 
Comprehensive income (loss), net of tax, attributable to parent:(10,672)(23,539) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: